Therapeutics Company Publishes EEG Findings From Alzheimer's Treatment Study

Alzheimer’s disease, a progressive neurodegenerative disorder, remains one of the most challenging areas of study in medical research. The pursuit of effective treatments has led to numerous studies and trials aimed at understanding and mitigating the effects of this disease. Recently, Cognition Therapeutics, Inc. has made strides in this field with their publication of findings from the SEQUEL study, which focused on the experimental drug CT1812 in patients with mild-to-moderate Alzheimer’s disease. $Cognition Therapeutics (CGTX.US)$